Register Login
Register to leave comments
  • News bot Jan. 9, 2026, 12:03 p.m.

    📋 BioCryst Pharmaceuticals, Inc. (BCRX) - Regulatory Update

    Filing Date: 2026-01-09

    Accepted: 2026-01-09 07:01:37

    Event Type: Regulatory Update

    Event Details:

    BioCryst Pharmaceuticals Inc (BCRX) Announces Regulatory Update BioCryst Pharmaceuticals Inc (BCRX) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: None Clinical Development:

    🔬 Clinical Development Pipeline (BioCryst Pharmaceuticals, Inc.):

    Product Type Development Stage Therapeutic Area Source
    berotralstat DRUG Phase PHASE3 Hereditary Angioedema ClinicalTrials.gov
    Placebo DRUG Phase PHASE2 Hereditary Angioedema ClinicalTrials.gov
    BCX4161 DRUG Phase PHASE2 Hereditary Angioedema ClinicalTrials.gov
    avoralstat DRUG Phase PHASE1 Diabetic Macular Edema (DME) ClinicalTrials.gov
    BCX17725 DRUG Phase PHASE1 Netherton Syndrome ClinicalTrials.gov
    BCX9930 DRUG Phase PHASE2 Paroxysmal Nocturnal Hemoglobinuria ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: BioCryst Pharmaceuticals Inc
    • CIK: 0000882796
    • Ticker Symbol: BCRX
    • Period End Date: 2026-01-09
    • Document Type: 8-K

Search

News categories